Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

AbbVie-partnered Calico unveils first licensing deal

Google’s healthcare research business gains rights to drug prospects in neurodegeneration

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Gopa Mitra retires from PAGB

She steps down after 34 years at organisation

- PMLiVE

The definition of value

Aligning the thoughts of biopharma and other healthcare stakeholders

- PMLiVE

Dive in: gaining leadership in a therapeutic area

Gaining long-term leadership in a therapy area can be commercially invaluable

- PMLiVE

Mylan buys US rights to blood clot drug

$300m deal to acquire Arixtra from South Africa’s Aspen

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

Baxter names biopharma spin-off Baxalta

Will separate from medical technology business

EU flag

Lantus faces first biosimilar rival in Europe

Sanofi prepares for insulin challenge from Boehringer and Lilly

- PMLiVE

Liberation strengthens team with new member

Edward Mullin has been appointed as account coordinator

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links